Ferring Pharmaceuticals, Inc.
400 Rella Boulevard
54 articles with Ferring Pharmaceuticals, Inc.
Rob Dunn, a professor of applied ecology at North Carolina State University in Raleigh recently wrote a book, Never Home Alone. In this book, he describes how millions of microorganisms, bacteria, fungi, viruses, parasites and insects live in your home—and in and on your body.
INVO Bioscience Enters Exclusive U.S. Licensing Agreement with Ferring Pharmaceuticals to Commercialize the Novel INVOcell™ System for Use in the Treatment of Infertility
INVO Bioscience, Inc. and Ferring Pharmaceuticals announced today that the companies have entered into an exclusive U.S. commercialization rights agreement for INVOcell.
NOCDURNA® (desmopressin acetate) Sublingual Tablets Now Available by Prescription in US for Treatment of Nocturia Due to Nocturnal Polyuria
NOCDURNA is the first and only sublingual tablet for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void.1
11/5/2018Biopharma companies make key appointments to fill leadership positions. Let's take a look!
Ferring Announces Retirement of Michel Pettigrew, President of the Executive Board and Chief Operating Officer
Michel Pettigrew, President of the Executive Board and Chief Operating Officer, will retire from his operational activities, effective December 31, 2018
Ferring will access Evotec’s integrated small molecule discovery and development platform to progress new molecules from concept to potential drug candidates
Rebiotix Clinical, Microbiome Data From First-In-Class Microbiota Restoration Therapy to Be Presented at IDWeek 2018
New data continues to underscore company leadership in microbiome field.
Arc Bio launched its proprietary antimicrobial resistance (AMR) software. It is the first in what it expects to be a series of next-generation sequencing (NGS)-based products for pathogen detection.
FDA Approves New Indications for ZOMACTON® (somatropin) as Ferring Plans Launch of Needle-Free Delivery System
Ferring Pharmaceuticals, Inc.. today announced that the U.S. Food and Drug Administration (FDA) has approved ZOMACTON (somatropin) for injection in four additional pediatric indications:
The U.S. Food and Drug Administration (FDA) was busy during the first half of this year with more than 20 novel drug approvals. Of those approvals, one-third came in June.
FDA’s Approval of T2 Biosystems T2Bacteria Panel Underlines Importance of Sepsis Diagnosis and Tr...
7/10/2018On May 29, the FDA cleared T2 Biosystems’ T2Bacteria Panel for diagnosis of sepsis. In that sepsis is the third-leading cause of death in the U.S., this emphasizes the importance of work in this area.
Rekovelle’s unique dosing algorithm, which is based on a woman’s anti-Müllerian hormone (AMH) level and body weight, is designed for predictable ovarian response
NOCDURNA® (desmopressin acetate) Now Approved by U.S. FDA as First Sublingual Tablet to Treat Nocturia due to Nocturnal Polyuria
The U.S. Food and Drug Administration (FDA) granted Ferring Pharmaceuticals Inc. approval to market NOCDURNA®.
Male Fertility Survey Reveals 80 Percent of Men Feel Overlooked When Experiencing Infertility Challenges
Ferring Pharmaceuticals Inc. (US) has announced findings from a survey conducted with RESOLVE: The National Infertility Association to better understand how men feel when struggling with their own or their partner’s infertility.
Ferring to Present Clinical Data on Efficacy and Safety of CLENPIQ™ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution for Colonoscopy Prep at Digestive Disease Week
Tuesday, June 5, 12:00-2:00 p.m., Dr. Lawrence Hookey to present "A Randomized, Assessor-Blinded, Multicenter Study Demonstrates the Efficacy and Safety of a New Ready-to-Drink Low Volume Bowel Preparation Prior to Colonoscopy" (Poster # Tu2010)
On May 1, the U.S. Food and Drug Administration (FDA) granted Scynexi’s oral formulation of SCY-078 to treat vulvovaginal candidiasis (VVC) and recurrent VVC both Qualified Infectious Diseases Product (QIDP) and Fast Track Designation.
Ferring Pharmaceuticals is buying Rebiotix. As part of the deal, will acquire Rebiotix’s lead program, RBX2660, a non-antibiotic treatment to prevent recurring Clostridium difficile infection (CDI).
Rebiotix’s RBX2660 is a non-antibiotic treatment in Phase 3 development for the prevention of recurrent Clostridium difficile infection (CDI) and has the potential to be the world’s first approved human microbiome product
Enteris BioPharma Initiates Feasibility Program with Ferring Pharmaceuticals to Develop an Oral Formulation of a Peptide
Agreement to Target New Oral Peptide Development Opportunity, Extending Successful Relationship between Enteris and Ferring